JOINT TRANSNATIONAL CALL 2017:

"Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to ✉
If you have any questions about this form, please do not hesitate to contact us at ✉

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Esra
Last name *	Erdal
Position *	Principal Investigator
Telephone number	+90 532 4474637
E-mail address*	esra.erdal@deu.edu.tr
Website address	http://www.ibg.deu.edu.tr/en/research/research-programmes/stem-cells-regeneration-homeostasis/esra-erdal-laboratory/
Institution/Organisation *	Izmir Biomedicine and Genome Center
Department*	Stem Cells, Regeneration & Homeostasis
Street	
Postal Code / City *	35340-Izmir
Country *	Turkey

***I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

☑ YES

SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal
Project title (draft): Fibrolamellar Hepatocellular Carcinoma Organoid Model to Drug Development
Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words): Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare liver cancer that usually occurs in adolescents and young adults who have no history of liver disease. Fibrolamellar has an incidence rate of 1 in 5,000,000 in the population at large. Recently, it has been shown that *DNAJB1-PRKACA* fusion kinase acts as an oncogenic driver and candidate drug target for FL-HCC. The aim of proposed project is to develop a 3D organoid model to perform drug screens and facilitate targeted drug development. Our team has experience on both CRISPR-Cas9 system and liver organoids.

OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

Our research focus is mainly to understand molecular mechanisms behind liver pathologies including cancer and metabolic disorders and to define new therapeutic targets. We have experience on the molecular and cell biology techniques and we recently have developed a novel method to produce iPSC-derived liver organoids to model urea cycle disorder, Citrulinemia.

Our team also has strong collaboration with clinicians from Gastroenterology and Liver Transplant Surgery Department of Faculty of Medicine Hospital at three biggest Universities in Turkey, Dokuz Eylul University, Ege University and Çukurova University.